Given the therapeutic importance and potential for optimizing pharmaco therapies against depression, research labs at AbbVie, Servier, Pfizer, and Alkermes revisited the question of whether ketamine activates mTOR using PFC synaptosomes. This evidence concerns the gene MTOR and major depressive disorder.